Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vinblastine + vincristine + prednisone + daunorubicin
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of vinblastine, vincristine, prednisone, and daunorubicin. This combination of drugs targets rapidly dividing cancer cells through different mechanisms. Vincristine and vinblastine are plant alkaloids that interfere with cell division by preventing microtubule formation. Daunorubicin is an anthracycline that prevents DNA replication in cancer cells. Prednisone is a corticosteroid that can kill cancer cells and help manage side effects of chemotherapy.
02
Targets
GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vinblastine + vincristine + prednisone + daunorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vinblastine + vincristine + prednisone + daunorubicin.